PSYCHIATRIC MANAGEMENT IN PRIMARY CARE. Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust

Similar documents
Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Document Title Pharmacological Management of Generalised Anxiety Disorder

Pharmacological Treatment of Anxiety & Depressive Disorders

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Anxiety Disorders: First aid and when to refer on

Mental illness A Broad Overview. Dr H Pathmanandam March 2017

Volume 4; Number 5 May 2010

Anxiety Disorders.

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

Treatment of Anxiety (without benzos)

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

Psychiatric Treatment of the Concussed Athlete

Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 3 October 2014)

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013

Depression & Anxiety in Adolescents

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

A Basic Approach to Mood and Anxiety Disorders in the Elderly

Depression in adults: treatment and management

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG

Depression: selective serotonin reuptake inhibitors

Mental Health Pathway

Treating Anxiety Disorders. Adil Virani, BSc (Pharm), Pharm D, FCSHP

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Major Depressive Disorder (MDD) in Children under Age 6

Guidance on the use of Antidepressants for the Treatment of Unipolar Depression and Anxiety Spectrum Disorders in adults (Version 4.

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Medication Management. Dr Ajith Weeraman MBBS, MD (Psychiatry), FRANZCP Consultant Psychiatrist Epworth Clinic Camberwell 14 th March 2015

Depression in Late Life

Introduction to Drug Treatment

How to Manage Anxiety

Disclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Antidepressant Treatment of Depression

Antidepressant Selection in Primary Care

Recommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2)

Presentation is Being Recorded

Children s Hospital Of Wisconsin

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

Anti-Depressant Medications

This initial discovery led to the creation of two classes of first generation antidepressants:

Treatment Options for Bipolar Disorder Contents

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Major Depressive Disorder (MDD) in Children under Age 6

Overview. Part II: Part I: Screening for Depression and Anxiety Risk Assessment Diagnosis of Depressive Disorders

Pharmacological treatment of anxiety disorders where is

DIAGNOSTIC CRITERIA (ICD 10)

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Anxiety Disorders.

Some newer, investigational approaches to treating refractory major depression are being used.

Antidepressant Selection in Primary Care

Depression Workshop 26 January 2007

Management Of Depression And Anxiety

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90

How to treat depression with medication: Some rules of thumb

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Partners in Care Quick Reference Cards

Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant

Psychiatry in Primary Care: What is the Role of Pharmacist?

BRIEF SUMMARY CONTENT

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

Start Low, Go Slow but Treat to Target

Depression: management of depression in primary and secondary care

A guide to reducing or stopping mental health medication. Notes for prescribers

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg91

AN OVERVIEW OF ANXIETY

Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Short Clinical Guidelines: General Anxiety Disorder (GAD)

Depression in Older Adults. Paul Boulware, MD Arizona Neurological Institute April 22, 2012

Mixing and Matching: Layering Medications as Family Physicians

Psychotropic Medication Use in Dementia

Intro to Concurrent Disorders

Common Antidepressant Medications for Adults

Antidepressants Choosing the Right One


Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Anxiolytics. What s new? Lindsey Sinclair

Quick Guide to Common Antidepressants-Adults

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

Objectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:

Adult Depression - Clinical Practice Guideline

VA/DOD CLINICAL PRACTICE GUIDELINE

MOOD (AFFECTIVE) DISORDERS and ANXIETY DISORDERS

Diabetes and Depression. Roshini Pinto-Powell, MD Stephen Noyes, LICSW, LADC William Gunn, PhD Beverly Bean, RN, C

Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)

Affective Disorders.

DEMENTIA AND MEDICATION

Mood Disorders.

Mentoring Session: Participant Cases

POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital

Transcription:

PSYCHIATRIC MANAGEMENT IN PRIMARY CARE Dr Fayyaz Khan MBBS, MRCPsych, MSc Consultant Psychiatrist (Locum) Mersey Care NHS Trust

Areas to cover Mood Disorders Anxiety Disorders Miscellaneous Conditions

Objectives 1. Practical tips in managing them in Primary Care. 2. When to refer. 3. Overview of National Guidelines.

MOOD DISORDERS

Diagnosis-ICD 10-Depression Key Symptoms (must have at least 2 of these) Low mood Anhedonia Fatigue Other Symptoms Disturbed sleep Poor appetite Poor concentration Reduced self esteem and self confidence Ideas of guilt, worthless Ideas of self harm or suicide Psychomotor agitation or retardation

Duration 2 weeks Degree- Number, Severity Mild= 4 symptoms Mod= 5-6 Sev= 7+ (with or without psychosis)

Treatment Approach Bio Psycho Social

Stepped-care model -NICE Focus of the intervention STEP 4: Severe and complex [a] depression; risk to life; severe selfneglect STEP 3: Persistent subthreshold depressive symptoms or mild to moderate depression with inadequate response to initial interventions; moderate and severe depression STEP 2: Persistent subthreshold depressive symptoms; mild to moderate depression STEP 1: All known and suspected presentations of depression Nature of the intervention Medication, high-intensity psychological interventions, ECT, crisis service, combined treatments, multiprofessional and inpatient care Medication, high-intensity Figure 1 The stepped-care mode psychological interventions, combined treatments, collaborative care and referral for further assessment and interventions Low-intensity psychosocial interventions, psychological interventions, medication and referral for further assessment and interventions Assessment, support, psychoeducation, active monitoring and referral for further assessment and interventions [a] Complex depression includes depression that shows an inadequate response to multiple treatments, is complicated by psychotic symptoms, and/or is associated with significant psychiatric comorbidity or psychosocial factors.

How do AD work? Increase levels of Serotonin & Noradrenaline

Types of AD SSRI- Fluoxetine, Citalopram, Sertraline SNRI- Duloxetine, Venlafaxine NRI- Roboxetine TCA- Amitriptyline, Dosulepin Other-Mirtazapine

Anti Depressants Do not use antidepressants routinely to treat persistent subthreshold depressive symptoms or mild depression because the risk benefit ratio is poor. NICE 1st Line: SSRI No effect/poorly tolerated: Another SSRI or different Class

AD-Swapping & Stopping 5,6 When changing from one antidepressant to another, abrupt withdrawal should usually be avoided. Cross-tapering is preferred, in which the dose of the ineffective or poorly tolerated drug is slowly reduced while the new drug is slowly introduced. In some cases cross-tapering may not be considered necessary. An example is when switching from one SSRI to another. Potential dangers of simultaneously administering two antidepressants include pharmacodynamic interactions (serotonin syndrome, hypotension, drowsiness) and pharmacokinetic interactions (e.g. elevation of tricyclic plasma levels by some SSRIs).

changing from tricyclics (TCA) citalopram/esc italopram fluoxetine paroxetine to tricyclics cross taper cautiously cross taper cautiously stop fluoxetine. Start tricyclic at very low dose and increase very slowly cross taper cautiously with very low dose of tricyclic to citalopram/esc to fluoxetine to paroxetine to sertraline to venlafaxine to mirtazapine italopram halve dose and add citalopram (or escitalopram) then slow withdrawal stop fluoxetine. Wait 4-7 days; start citalopram at 10mg per day (or escitalopram 5mg per day) and increase slowly withdraw paroxetine then start citalopram 10mg per day (or escitalopram 5mg per day) halve dose and add fluoxetine then slow withdrawal withdraw citalopram (escitalopram) then start fluoxetine withdraw paroxetine then start fluoxetine halve dose and add paroxetine then slow withdrawal halve dose and add sertraline then slow withdrawal withdraw withdraw citalopram citalopram (escitalopram) (escitalopram) and then start and then start paroxetine at 10 sertraline at 25 mg per day mg per day stop fluoxetine. Wait 4-7 days; start paroxetine at 10mg per day and increase slowly stop fluoxetine. Wait 4-7 days; start sertraline at 25 mg per day and increase slowly withdraw paroxetine then start sertraline at 25 mg per day cross taper cautiously starting with 37.5 mg per day cautious crosstapering recommended (4) withdraw and then start cautious crosstapering venlafaxine at 37.5 mg per day. recommended Increase very (4) slowly stop fluoxetine. cautious crosstapering Wait 4-7 days; start recommended, venlafaxine at start 37.5 mg per day. mirtazapine at Increase very 15mg daily (4) slowly withdraw paroxetine. Start venlafaxine at 37.5 mg per day. Increase very slowly cautious crosstapering recommended (4)

sertraline venlafaxine mirtazapine cross taper cautiously with very low dose of tricyclic cross taper cautiously with very low dose of tricycli cautious crosstapering recommended, using very low starting dose for tricyclic (4) withdraw sertraline then start citalopram 10mg per day (or escitalopram 5mg per day) cross taper cautiously. Start with citalopram 10 mg per day (or escitalopram 5mg per day) cautious crosstapering recommended (4) withdraw sertraline then start fluoxetine crosss taper cautiously. Start with 20 mg every other day cautious crosstapering recommended (4) withdraw sertraline then start paroxetine 10mg per day cross taper cautiously. Start with 10 mg per day. cautious crosstapering recommended (4) cross taper cautiously. Start with 25 mg per day cautious crosstapering recommended (4) withdraw sertraline then start venlafaxine at 37.5 mg per day cautious crosstapering recommended (4) cautious crosstapering recommended (4) cautious crosstapering recommended (4) stopping/with drawing of ticyclics particular reduce over antidepressant four weeks (4) s citalopram/esc italopram reduce over one to four weeks (4) fluoxetine at 20mg per day - just stop at 40 mg per day, reduce over four weeks paroxetine reduce over four weeks, or longer if necessary * sertraline reduce dose gradually over one to four weeks (4) venlafaxine reduce over four weeks or longer if necessary (2,4) mirtazapine reduce dose gradually over 4 weeks (4)

Clinical Scenarios 32 years old male with moderate depression has tried fluoxetine 20mg od as first anti depressant for 4 weeks and there has been no improvement. What is the next best step? 1) Wait for another 2-4 weeks for response. 2) Increase the dose. 3) Try a different AD.

Response time for AD? It is widely held that AD do not exert their effect for 2-4 weeks. This is a myth. All AD show a pattern of response where the rate of improvement is highest during weeks 1-2 and lowest during weeks 4-6. The Maudsley Prescribing Guidelines, 12 th edition-page-233

British Assoc Psychopharmacology Lack of significant improvement after 2-4 weeks treatment reduces the probability of eventual sustained response. After 4 weeks adequate treatment: if there is at least some improvement continue treatment with the same AD for another 2-4 weeks. if there is no trajectory of improvement undertake a next step (higher dose or different AD) After 6-8 weeks adequate treatment: if there is moderate or greater improvement continue same treatment. if there is minimal improvement undertake a next step (higher dose or different AD)

Clinical Scenario 40 years old female with moderate depression did not respond to citalopram. Has been now treated with fluoxetine 40mg for 4 weeks and there is no response. What is the next best step? Increase dose of fluoxetine to 60mg. Change to different class of AD.

Evidence of high dose SSRI in Major Depression High dose AD treatment for patients refractory to medium dose is not recommended for SSRI. 2

Clinical Scenario 35 years old lady, has been feeling low for 8 wks, following change of role at work. She took this change as a failure and developed feeling of worthlessness. She started making mistakes at work and was experiencing occasional thoughts of life is not worth living, but did not made any attempts to end her life and continued to work. She is able still to complete her household chores, but does get easily tired and is struggling to look after her 6 years old son. She was prescribed fluoxetine 20mg od, which she stopped after 1 week due to side effects of nausea. What is your diagnosis and management plan?

Clinical Scenario 60 years old female patient, on Haloperidol for Schizophrenia, presents with major depression. Which AD s are contraindicated?

Clinical Scenario 60 years old female, with history of IHD, is currently on erythromycin, presents with major depression. Which AD s are contraindicated?

Clinical Scenario 50 years old female patient, on ritonavir (anti retroviral), presents with major depression. Which AD s are contraindicated?

Clinical scenario 25 years old female presents to you with low mood, suicidal thoughts and intense feeling of worthlessness after splitting up with her boyfriend of 3 months. During consultation she was very emotional and hopeless. She reports to you that she has tried several anti depressants in the past without much benefit. What is your management plan?

DM & Depression 55 years old diabetic, female with history of major depression and poor response to x2 SSRI. Which AD should be avoided?

HTN & Depression 55 years old male with Hypertension, history of major depression and poor response to x2 SSRI. Which AD should be avoided?

Average duration between onset and diagnosis of BPAD? 6 years: UNSW Australia and Italian study published in the Canadian Journal of Psychiatry, July 2016.The meta-analysis of 9,415 patients from 27 studies, the largest of its kind. Some studies have quoted up to 10 years.

When to refer to Mental Health Services NICE: Referral to specialist mental health services should normally be for people with depression: who are at significant risk of self-harm, have psychotic symptoms, require complex multi-professional care, or where an expert opinion on treatment and management is needed. With history of mania and hyopmania

Anxiety Disorders GAD Panic Disorder PTSD OCD Social Phobia

GAD, PD, OCD (NICE): Psychological therapy is more effective than pharmacological therapy and should be used as first line where possible. SSRI s & Venlafaxine across the range of Anxiety Disorders.

GAD 4 Reassurance Anxiety Mx including relaxation training, exposure therapy CBT Exercise

GAD 4 Emergency Mx: BZD (2-4 weeks) First Line SSRIs Venlafaxine Duloxetine Mirtazapine Pregabalin Other: Buspirone (negligible sedative, 4 wks of 10mg TDS) B- Blockers (somatic sx) Quetiapine

PD 4 CBT Anxiety Mx including relaxation training Combination- not consistently better than pharmacological alone

Panic Disorders 4 Emergency Mx: BZD (rapid effect, NICE does not recommend) First Line SSRIs Other: Venlafaxine Mirtazapine TCA (imipramine, clomipramine)

PTSD 4 Debriefing Counselling Anxiety Mx CBT EMDR

PTSD 4 Emergency Mx: Not usually appropiate First Line SSRIs Other: Mirtazapine Venlafaxine Duloxetine Clomipramine Anti psychotic (as augmentation)

OCD 4 Exposure therapy Behavioural therapy CBT Combination- Most effective

OCD 4 Emergency Mx: BZD (Not usually appropriate) First Line SSRIs Clomipramine Other: Citalopram with Clomipramine Anti Psychotic with AD Mirtazapine with AD (NICE)

Clinical scenario A 45 years old lady with a OCD of moderate severity, not keen on psychological therapy was prescribed fluoxetine 20mg od. She was followed up in 4 weeks time and there was no improvement. What will you do? Increase the dose or Change medication

Continue The dose was increased to 40mg OD, she was followed up after 4 weeks and still reports no improvement. What will you do now? Increase the dose or Change medication

Continue She was trialled on Sertraline 50mg od for 4 weeks and still no improvement. What will you do now? Increase the dose or Change medication

Continue Sertraline was gradually increased to 200mg od over 10 week period and there was not any significant improvement. What will you do now? Change medication. Wait longer Refer to Secondary Mental Health Services.

Dose response of SSRI in OCD Compared with low or medium doses, high doses of SSRI were associated with improved treatment efficacy.1

The American Psychiatric Association Practice Guidelines recommend higher target doses of SSRIs in the treatment of OCD than they do for depression. 3 High doses usually needed, at least 12wks for treatment response. 5

Social Phobia 4 CBT Exposure therapy Combination- More effective

Social Phobia 4 Emergency Mx: BZD (PRN) First Line SSRIs Pregabalin Gabapentin Other: BZD with SSRI Propranolol (performance anxiety) Venlafaxine Olanzapine

Insomnia Difficulty in initiating and maintaining sleep. Symptom of underlying problem. Identify and Treat the cause. Emphasis on sleep hygiene

Sleep Hygiene Avoid: Excessive caffeine, alcohol, nicotine 3-6 hrs before bed. Daytime nap. TV/Ipad/Phones 1 hr before bed. Strenuous exercise or mental activity near bed time. Prolonged periods in bed if not asleep. Promote: Bedtime routine, comfortable environment, warm bath, light exercise.

BNF Listed Z : Zopiclone, Zolpidem BZD: Nitrazepam, Temazepam Anti Histamines: Promethazine (low abuse potential) Melatonin ( Circadin 2mg, 55 and above, up to 13 wks)

Minimise Polypharamacy Stress Incontinence & Depression Duloxetine Diabetic Neuropathy & Depression Duloxetine Peripheral & Central Neuropathic Pain and GAD Pregabalin Seizures and GAD Pregabalin

Insomnia and Depression Mirtazapine, TCA, Trazadone

Thank you

References 1. Meta analysis of dose response of SSRI in OCD. J F Leckman & C Pitteger. Molecular Psychiatry 15, 850-855 (2010) 2.Is dose escalation of antidepressants a rational strategy after a medium dose treatment has failed? European Archives of Psychiatry and Clinical Neuroscience, December 2005, Volume 255, issue 6, pp 387 400 3. American_Psychiatric_Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. American Psychiatric Association: Arlington, VA, 2007. 4. The Maudsley Prescribing Guidelines, 12 th Edition. 5. Oxford Handbook of Psychiatry, 3 rd edition. 6. GP Notebook